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Abstract 
Background: Technical limitations for culturing the human malaria parasite Plasmodium vivax have impaired the 
discovery of vaccine candidates, challenging the malaria eradication agenda. The immunogenicity of the M2 domain 
of the Merozoite Adhesive Erythrocytic Binding Protein (MAEBL) antigen cloned from the Plasmodium yoelii murine 
parasite, has been previously demonstrated.
Results: Detailed epitope mapping of MAEBL through immunoinformatics identified several MHCI, MHCII and B cell 
epitopes throughout the peptide, with several of these lying in the M2 domain and being conserved between P. vivax, 
P. yoelii and Plasmodium falciparum, hinting that the M2-MAEBL is pan-reactive. This hypothesis was tested through 
functional assays, showing that P. yoelii M2-MAEBL antisera are able to recognize and inhibit erythrocyte invasion from 
both P. falciparum and P. vivax parasites isolated from Thai patients, in ex vivo assays. Moreover, the sequence of the 
M2-MAEBL is shown to be highly conserved between P. vivax isolates from the Amazon and Thailand, indicating that 
the MAEBL antigen may constitute a vaccine candidate outwitting strain-specific immunity.
Conclusions: The MAEBL antigen is promising candidate towards the development of a malaria vaccine.
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Malaria is one of the most nefarious infectious diseases 
of humans and continues to have a devastating global 
impact upon health and well-being, mainly among chil-
dren under the age of five and pregnant women. Annu-
ally, about 200 million cases are reported and almost 
600,000 deaths occur [1]. Despite the recent relative 
progress towards a Plasmodium falciparum vaccine, the 
development of a vaccine to protect individuals from 
Plasmodium vivax is still incipient, jeopardizing the 
Malaria Vaccine Roadmap [2], and consequently the 
whole malaria eradication agenda. Currently, the diffi-
culty to grow P. vivax in vitro for long periods [3] chal-
lenges ongoing strategies for identification of novel 
vaccine candidates against this parasite. Consider-
ing these roadblocks, an approach to develop vaccines 
against P. vivax might rely on the use of malaria antigens 
conserved amongst species.
Recently, the immunogenicity of M2 MAEBL (Mero-
zoite Adhesive Erythrocytic Binding Protein) domain 
of Plasmodium yoelii has been demonstrated. This vac-
cine candidate conferred 90% protection in immunized 
mice after lethal challenge and corresponding antisera 
inhibited significantly erythrocyte invasion by P. yoelii 
[4]. MAEBL is a membrane protein that belongs to the 
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erythrocyte binding protein (ebl) family [5–8] and exhib-
its homologous regions to the DBL-EBP (Duffy binding 
like–Erythrocyte binding protein) and to the apical mem-
brane antigen 1 (AMA1) [7–9]. MAEBL is a conserved 
antigen expressed in blood-stage late forms, in the sali-
vary gland sporozoite and also during the late liver stage 
[10, 11].
Immunoinformatics, in which computational 
approaches select the most appropriate vaccine candidate 
and algorithms predict T- and B-cell immune epitopes 
[12], is an alternative to overcome limitations imposed by 
the lack of knowledge in terms of P. vivax biology.
Here, an immunoinformatics strategy was used, that 
identified the MAEBL antigen as a promising interspe-
cies and interstrain malaria vaccine candidate and the 
pan-reactivity of the P. yoelii M2-MAEBL antisera against 
P. falciparum and P. vivax was investigated.
Methods
B‑cell and T‑cell epitope prediction
Fine epitope mapping through bioinformatics
The predicted entire MAEBL protein sequence of 
the rodent malaria parasite P. yoelii, available at Plas-
moDB (PYYM_0902200.1) was initially used to predict 
C57BL/6  J mouse MHC epitopes for H-2Kb, H-2Db 
(MHC class I) and IA-b alleles (MHC class II). Predic-
tions for linear B lymphocyte epitopes were also ran. 
Detailed procedures were as follows.
MHC class I and II epitope mapping
Rankpep software [13–16] set to a binding threshold of 
3% and proteasome cleavage filter “ON” was used for 
initial MHC class I epitope screening. Subsequently, the 
MAEBL protein was re-screened using IEDB [17, 18], 
NetMHCpan [19, 20], Bimas [21, 22], MAPPP [23, 24] 
and PropredI [25]. All epitopes that were identified using 
all softwares were thus selected as those presenting the 
highest confidence.
Rankpep was also used to predicted MHC class II 
epitopes, with a binding threshold set to 3% and protea-
some cleavage filter “OFF”. Resulting predicted epitopes 
with a score above 9.52 was selected for further analyses 
using IEDB [17, 18] and NetMHCII [26–28]. Epitopes 
displaying the best scores generated between all screens 
were included in the final list.
B‑cell epitope mapping
The BCPRED resource [29, 30] was employed to identify 
B-cell epitopes with a size of 20 aminoacids, set to a 75% 
specificity. After identifying the best predicted epitopes 
based on score, each of these epitopes was screened for 
predicted antigenicity using the VaxiJen v.2 software [31], 
under a 0.5 threshold and the “parasite model” filter on, 
according to previously published recommendations [32, 
33]. Subsequently, all epitopes presenting scores above 
0.5 were included in the final list. Lastly, the potential 
conservation within each of these epitopes between P. 
yoelii and P. falciparum, and between P. yoelii and P. vivax 
was investigated, using the BLAST tool at PlasmoDB, and 
epitopes were considered homologous between P. yoelii 
and any of the other two human parasites when amino 
acid identity was higher than 50%.
Immunization regimen
C57BL/6 mice with 5–7  weeks-old were injected sub-
cutaneously four times at 3 weeks intervals with 5 μg of 
rPyM2-MAEBL emulsified in 1:1 (vol/vol) complete Fre-
und’s adjuvant (CFA) for the first dose or incomplete Fre-
und’s adjuvant (IFA) in the subsequent doses [4].
The prime-boost (PB) group received the first dose of 
100 μg pIgSPM2 intramuscular, followed by three doses 
of 5  μg of rPyM2-MAEBL in IFA. As control groups, 
animals were injected with 1:1 (vol/vol) adjuvant (CFA/
IFA), pIgSPM2 or only pIgSP vector. Sera from immu-
nized mice were collected immediately before each dose 
and 3  weeks after the last dose. There was no signifi-
cantly difference in protection between the rM2-MAEBL 
and the prime-boost regimen. All experiments and pro-
cedures were performed in accordance with relevant 
guidelines and regulations of the Ethical Committee for 
Animal Research of the University of Campinas and were 
approved under Protocol No. 1437-1.
Slide preparation and immunofluorescence assays (IFA)
Clinical isolates of P. vivax and P. falciparum infected 
blood from malaria patients were collected at Shoklo 
Malaria Research Unit (Thailand) with written informed 
consent. The thin smears used for the IFA were prepared 
from ex vivo matured schizonts concentrated by 45% Per-
coll for P. vivax and 70% Percoll for P. falciparum [3, 34] 
that were diluted 1:4 with uninfected RBCs. Immuno-
fluorescence assays were performed after fixing the blood 
smears with ice-cold acetone for 20  min and air-dried. 
Well diameters were established with the aid of a Dako-
Pen (Dako), and blocking was performed by 30-min 
incubation at 37 °C with PBS containing 3% BSA (USB). 
C57BL/6 mice with 5–7  weeks-old were immunized as 
described elsewhere [4] and pooled sera from the differ-
ent immunization groups were diluted 1:50 in PBS sup-
plemented with 3% BSA and applied to the slides for 1 h 
at 37  °C. Slides were washed 3X in PBS and incubated 
with Alexa-568 goat anti-mouse IgG (Invitrogen) for 1 h 
at 37  °C in the dark, then washed 3X in PBS and incu-
bated with DAPI (4′,6-diamidino-2-phenylindole, dihy-
drochloride-(Invitrogen) diluted in ultrapure (Millipore) 
water for 10  min at room temperature. After another 
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round of washing, Fluorosave (Caliobiochem) was added, 
and slides were sealed with coverslips. Parasites were 
visualized with the aid of a Nikon TS100 epifluorescence 
microscope. All samples above were collected in accord-
ance with relevant ethical guidelines and regulations of 
the University of Oxford, Centre for Clinical Vaccinology 
and Tropical Medicine and the Ethics committee of Fac-
ulty of Tropical Medicine, Mahidol University, under the 
approved protocols OXTREC 027-025 and MUTM 2008-
215 from.
Plasmodium‑specific antibody binding assay
Transfection
Transfection of HEK293 cells to obtain cells expressing 
PvMAEBL, PfMAEBL, PfSEA or PVX_113775 on the 
cell surface was as previously described [35]. Nucleo-
tide sequences encoding for PvMAEBL (PVX_092975: 
amino acid 540–1007), PVX_113775 (amino acid 1–358), 
PfMAEBL (PF3D7_1147800: amino acid 958–1249) and 
PfSEA (PF3D7_1021800: amino acid 810–1083) were 
amplified via PCR, using either P. vivax UMS203 or P. 
falciparum 3D7 RNA as template, and cloned into the 
pDisplay vector (Invitrogen). The resultant plasmids were 
then transfected into HEK293 cells using lipofectamine 
2000 (Invitrogen) for surface expression of the antigens.
Antibody binding assay
The antibody binding assay was as previously described 
[35]. Briefly, transfected cells, expressing the antigens 
on the cell surface, were first incubated with the serum 
(diluted 1:100 in FACS blocking buffer (10% FBS in PBS) 
on shaking. The cells were then incubated with a dou-
ble stain, consisting of Alexa Fluor 488-coupled second-
ary antibodies (Invitrogen; diluted 1:500) and propidium 
iodide (PI; diluted 1:2500) on shaking. Cells were read on 
Accuri C6 (BD Biosciences) and analysed using FlowJo 
(Tree Star).
Ex‑vivo functional invasion assays
Plasmodium falciparum isolates
The preparation of schizonts concentrate after 70% Per-
coll was mixed with target cells (RBCs/uninfected eryth-
rocytes) in the ratio 1:12. The solution was diluted with 
2% haematocrit using McCoy 5A 10% human AB serum 
(inactivated) and cultivated in microplates in a volume of 
200 µl, 5% O2 at 37.5° C for 12 h. The inhibitory poten-
tial of anti-PyM2-MAEBL antibodies were tested by 
adding the fourth pool of sera from animals immunized 
with a dose of the rPyM2-MAEBL protein alone or in 
heterologous prime-boost system at the 1:50 dilution to 
the final mixture invasion assay. It was used as a control 
serum pool of the 4th dose animals of ACF/AIF group. 
As positive control, it was used 100 μM of E64 (Sigma), a 
protease inhibitor, to ensure no disruption of schizonts. 
At the end of the test were made blood smear slides of 
each well stained with Giemsa (Sigma). The number 
of rings/trophozoites to 1000  cells was determined by 
microscopic analysis.
Plasmodium vivax isolates
20  ml of cord blood were collected in heparin tube 
immediately after the newborn delivery. Samples were 
collected after informed consent was obtained from each 
subject and in accordance with relevant guidelines and 
regulations of the  ethics committee of the Fundação de 
Medicina Tropical—Dr. Heitor Vieira Dourado (protocol 
CAAE-0044.0.114.000-11).
The blood group was determined by using a standard 
ABO Kit (EBRAN). After plasma removal, the cells were 
washed in McCoy 5A medium (Sigma) and haemato-
crit adjusted to 50% using McCoy 5A. Leukocytes and 
platelets were depleted by two passages in CF11 filtra-
tion column (Whatman). Red cells from umbilical cord 
were again adjusted to 50% haematocrit and carefully 
overlaid on tubes containing 70% Percoll (GE Health-
care). According to Russell et  al. [3], the preparation of 
schizonts concentrate after 45% Percoll enrichment was 
mixed with target cells (cord blood) in the proportion 
1: 6. The solution was diluted to 2% haematocrit using 
McCoy 5A (Sigma) 20% human AB serum (inactivated) 
and cultivated in microplates in a volume of 200 µl 5% O2 
at 37.5 °C for 24–30 h depending on the parasite matura-
tion. The inhibitory potential of anti-PyM2-MAEBL anti-
bodies were tested by adding the fourth dose pool sera 
from animals immunized with rPyM2-MAEBL protein 
alone or in heterologous prime-boost system at the 1:50 
dilution to the final mixture invasion assay. It was used 
as a control sera pool of the 4th dose animals of ACF/AIF 
group. As a positive control of inhibition was used poly-
clonal anti-P. vivax Duffy Binding Protein (PvDBP) IgG 
[36]. At the end of the test blood smear slides of each well 
were performed and stained with Giemsa (Sigma). The 
number of rings/trophozoites from 1000 cells was deter-
mined by microscopic analysis.
Amplification and maebl sequencing from Amazonian 
isolates
A total amount of nine blood samples were collected 
(during the period of 2012–2014) from different areas 
in the Amazon: the cities of Manaus in the Amazonas 
state and Mâncio Lima and Acrelândia, both in state 
of Acre (Fig.  1). The identification of P. vivax species 
was performed by nested-PCR as previously described 
[37]. For Pv-MAEBL amplification, oligonucleotides 
were designed based on the Pv-MAEBL Sal-1 strain 
(PVX_092975) sequence from PlasmoDB. Three DNA 
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fragments were PCR-amplified to obtain the sequence of 
M2-MAEBL domain. Oligonucleotide sequences used in 
this study are displayed in Additional file 1. Reactions to 
amplify fragments one and three were performed with 
Platinum Taq (Invitrogen). Amplification condition was 
as follows: 1 cycle of 5 min at 95 °C and 35 cycles of 30 s 
at 95  °C, 45  s at 58  °C, 1 min at 72  °C and a final cycle 
of 5 min at 72 °C. The fragment two was amplified using 
Phusion DNA Polymerases (Thermo Fisher Scientific). 
The PCR reaction was submitted to 1 cycle of 5  min at 
98 °C and 35 cycles of 15 s at 98 °C, 30 s at 59 °C, 1 min 
at 72 °C and a final cycle of 10 min at 72 °C. The purified 
PCR product was sequenced using 3730 ×  l DNA Ana-
lyzer (Applied Biosystems). All generated sequences were 
subjected to similarity search analysis by BLAST.
Alignment of the M2 maebl domain sequences of P. vivax
The MAEBL M2 domain of the nine isolates from Bra-
zilian Amazon (GenBank accession nos. KX061004 to 
KX061012) were compared to previously described 
sequences deposited in PlasmoDB: Thailand_VKBT-101, 
Thailand_VKBT-100, Thailand_VKTS-39 and the refer-
ence sequence Pv-MAEBL Sal-1 strain (PVX_092975), 
using the Clustal Multialin Interface Page [38].
Results
Detailed in silico epitope mapping of the P. yoelii Merozoite 
Adhesive Erythrocytic Binding Protein (MAEBL)
MHC class I and II epitope mapping
In silico epitope mapping identified two predicted 
epitopes for MHC class I, for each of the H-2Kb and 
H-2Db alleles (Additional file  2). Epitope QNYYSFTNL 
Fig. 1 Geographic areas in the Amazon where P. vivax samples were collected. Manaus, Mâncio Lima and Acrelândia indicated by arrows. The map 
was generated by the authors using CorelDRAW graphics suite X7 software
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for the H-2Kb allele presented the highest score between 
all programs used, whereas the NQNINLVKL epitope 
for allele H-2Db was among the top ten with the highest 
scores. Initial epitope screening for MHC class II using 
Rankpep resulted in the identification of 19 epitopes. 
However, after further analysis with IEDB and NetMH-
CII, only two epitopes were common between all soft-
wares (Additional file 2).
B‑cell epitope mapping
Using BCPRED, 35 predicted epitopes with a score above 
0.8 were identified. Each of these was further analysed 
using Vaxijen software in order to confirm antigenic-
ity, resulting in a total of 25 epitopes with a score higher 
than 0.5 (Additional file  3). BLAST searches with these 
epitopes against human malaria parasite sequences 
revealed that 12 epitopes present homology to both P. fal-
ciparum and P. vivax sequences. Although epitopes were 
largely scattered evenly throughout the peptide (Fig.  2), 
interestingly, 8 out of these 12 conserved epitopes fall 
within the M2 domain of MAEBL (Additional file  3, 
Fig. 2).
Immunofluorescence and invasion inhibition assays with P. 
falciparum and P. vivax isolates
Bearing in mind the conserved feature of MAEBL 
amongst Plasmodium species, investigated the abil-
ity of P. yoelii M2-MAEBL antisera pool was investi-
gated as previous described [39], to recognize blood 
schizonts of P. falciparum (3D7) and P. vivax harvested 
from infected patients. Their reactivity was analysed by 
indirect immunofluorescence assay (IFA). As shown in 
Figs.  3a, b, P. yoelii antisera raised against M2-MAEBL 
recombinant protein cross-react with both human para-
sites. Although the pattern observed at the IFA (Fig. 3a, 
b) is different from the one previously observed at the 
Leite et al. [4]. As a control, sera from mice injected with 
complete/incomplete Freund’s adjuvant (CFA/IFA) were 
used. To further validate the pan reactivity of the anti-
sera raised against the M2 region of the PyMAEBL pro-
tein the sera against HEK cells expressing on their surface 
PvMAEBL or PfMAEBL fragments or unrelated antigens 
was tested. Only HEK cells expressing the PvMAEBL and 
the PfMAEBL showed reactivity (Fig. 4). Next, to verify 
if M2-MAEBL antisera cross-reactivity could interfere on 
the parasite invasion process to erythrocytes, functional 
ex vivo invasion assays using two P. falciparum and four 
P. vivax isolates were performed. The MAEBL antisera 
inhibited up to 40–60% invasion of the FVT402 P. falci-
parum isolate; however, no inhibition was observed for 
the MKK183 isolate (Fig. 3c). Nevertheless, Prime Boost 
(PB) (described in “Methods” section) or MAEBL anti-
sera inhibited at higher levels the FVT402 isolate than 
the 3D7 P. falciparum culture. As expected, no newly 
invaded erythrocytes were observed when the protease 
inhibitor E64 was added to the assays. Functional inva-
sion analyses using different P. vivax isolates (Fig.  3d) 
demonstrated that P. yoelii M2-MAEBL antisera (PB 
and MAEBL) inhibited erythrocyte invasion by most of 
the isolates tested. Inhibition levels (up to 90%) observed 
were comparable to anti-Duffy antibodies, which block 
the DARC receptor essential for P. vivax invasion, how-
ever no statistical difference was observed. In general, PB 
antisera inhibited invasion at higher levels than MAEBL, 
probably due to the difference between immunization 
regimens. No inhibition was observed in the presence of 
sera from mice immunized with only CFA/IFA.
Alignment of the M2 maebl domain sequences
The M2 maebl domain of P. vivax of nine patients from 
three different areas in the Amazon was sequenced 
(Additional file  4). The isolates were compared to 
three Thai isolates as well as the reference strain Sal-1 
sequences previously deposited in PlasmoDB. A high 
degree of similarity was observed among all sequences, 
with only two SNPs differentiating the Brazilian and Sal-1 
sequences from Thai parasites (Additional file  4). These 
findings may largely explain the similar inhibitory levels 
observed in functional assays amongst different isolates 
and reinforce the validity of using the P. vivax Sal-1 strain 
genome available at PlasmoDB for immunoinformatics 
analysis.
Discussion
Functional assays from previous work have suggested 
that MAEBL is a suitable malaria vaccine candidate [4]. 
For this reason, MAEBL was studied in further detail 
here, through a conjugation of detailed epitope mapping 
Fig. 2 Schematic representation of the P. yoelii MAEBL antigen with locations of domains and in silico mapped B-cell epitopes. S Signal peptide, Rep 
Repetitive Domain; C- Cysteine-rich Domain, TM Transmembrane Domain, Cyt Cytoplasmic Domain, E B-cell epitope, CE conserved B-cell epitope
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in silico and further experimental evaluation. Epitope 
mapping identified four MHC classes I and II puta-
tive epitopes within the P. yoelii MAEBL antigen, which 
resulted from a consensus between different prediction 
programs. It has been shown that MAEBL is expressed 
not only in blood stages, but also in midgut and salivary 
gland sporozoites [11, 40, 41] suggesting that it may be 
important for the establishment of a successful pre-
erythrocytic infection of the parasite. As such, in light 
of the discovery of a malaria vaccine, selecting antigens 
that present MHC class I and II epitopes should be prior-
itized given the mounting evidence that antigen-specific 
CD8+ and CD4+ immune responses contribute for pro-
tection from sporozoite challenge both in animal models 
and human malaria [42]. In addition, it was determined 
that the MAEBL antigen contains at least 25 predicted 
B-cell epitopes that are likely to elicit antibody-depend-
ent immune responses, which have been widely shown to 
be important for protection against blood-stage antigens 
[42]. Although these epitopes were scattered throughout 
different domains of MAEBL, more than half of them 
(fourteen) are located within the M1 and M2 ligand 
domains, which have been confirmed to bind to mouse 
erythrocytes [9], suggesting their role in cell invasion. 
Moreover, all but one of these fourteen epitopes lying in 
the M1 and M2 domains are conserved between P. yoe-
lii, P. vivax and P. falciparum. It has been shown that a 
particular epitope (YVSSFIRPDYETKCPPRYPL) pre-
sent in the P. falciparum MAEBL M2 domain is highly 
immunogenic and capable of binding human HLA with 
high avidity [43]. Interestingly, the present bioinformat-
ics predictions identified an epitope with a very similar 












































Fig. 3 Plasmodium yoelii MAEBL antisera pan-reactivity against human malaria parasites. a rPyM2MAEBL antibodies recognize Plasmodium 
falciparum (3D7 strain) schizonts. b rPyM2MAEBL antibodies also recognize Plasmodium vivax schizonts. Sera pool from the 4th dose of animals 
immunized with rPyM2MAEBL, prime-boost regimen or of mice injected with adjuvant only (CFA/IFA) were used at a dilution of 1:50 in indirect 
immunofluorescence assays against P. falciparum or P. vivax schizonts. Sera from mice immunized with rPyM2-MAEBL or heterologous prime-boost 
system inhibit invasion by c P. falciparum to normocytes and d P. vivax to reticulocytes. Schizonts and target cells were cultured in vitro in the pres-
ence of sera pool from the fourth dose of immunized mice diluted 1:50. As a positive control for inhibition in P. vivax assays anti-Duffy polyclonal 
sera was used in 1:50 dilution. In P. falciparum, E64 protease inhibitor (Sigma) was used as positive control of inhibition. For both species sera from 
mice injected with CFA/IFA were used as a negative control. The parasitaemia was determined by counting at least 1000 red blood cells. The results 
are expressed as percentage inhibition compared to the control without sera
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sequence (SSFIRPDYETKCPPRYPL) that is conserved 
between P. yoelii, P. falciparum and P. vivax. Since the 
M2 peptide was used here in the immunization experi-
ments, the extant conservation of this and the other 
epitopes may largely explain the pan-reactivity observed 
and further suggests that this peptide may be a promising 
candidate for a malaria vaccine targeting more than one 
parasite species. In fact, previous experimental MAEBL 
epitope mapping revealed that anti-MAEBL IgM and IgG 
antibodies displayed strong responses against fragments 
located in the M2 region [4].
Plasmodium merozoites may use multiple pathways to 
invade red blood cells. The latter point is supported by 
data from previous experiments in which MAEBL knock-
out Plasmodium berghei strain ANKA parasites were 
still able to invade red blood cells in vivo [11]. Although 
erythrocyte invasion by Plasmodium merozoites seems 
to be largely host-specific, different Plasmodium spe-
cies keep several structurally and functionally homolo-
gous adhesins that play important roles during invasion, 
which enable them to, in some cases, invade red cells of 
heterologous host species [44]. It was shown that proteins 
from P. falciparum and P. yoelii bound to heterologous 
host red cell receptors, likely through their conserved 
motifs; suggesting homologies between Plasmodium 
ligands [44]. Bioinformatics analyses show high simi-
larities between the functional and genomic sequences 
across Plasmodium species [45, 46]. Also, studies suggest 
preservation of erythrocyte binding function of phyloge-
netically distant Plasmodium species [45]. These obser-
vations indicate that interspecies conserved epitopes that 
map within conserved functional motifs could be promis-
ing candidates for the development of effective vaccines.
MAEBL is an antigen expressed during the blood and 
liver stages and is essential for sporozoite invasion of 
mosquito salivary glands [11]. MAEBL is also impli-
cated in the invasion of merozoites into new erythro-
cytes, though not essential at this stage. The ability of 
anti-MAEBL antibodies to inhibit the invasion of mero-
zoites of P. falciparum was demonstrated here. Consider-
ing that MAEBL seems to be a highly conserved antigen 












Pre-immune serum Py-immune serum
Non-transfected  - - 
PfMAEBL - + 
PvMAEBL - + 
PfSEA - - 
PVX_113775 - - 
b c 
Fig. 4 Serum response against PfMAEBL and PvMAEBL. Pre-immune and PyMAEBL-immune mouse serum were probed against non-transfected 
HEK293 cells (negative control), HEK293 cells transfected for cell surface expression of PfSEA (negative control for Pf ), PVX_113775 (negative control 
for Pv), PfMAEBL or PvMAEBL and analysed by FACS. FL1 signal indicates specific binding (Alexa Flour 488 staining) while FL2 signal indicates dead 
cells. Representative plots for positive and negative serum response shown (a–c). As negative control, background IgG response (in black box) was 
observed a with PyMAEBL-immune serum against non-transfected live cells and b with PyMAEBL-immune serum against live cells expressing PfSEA, 
an antigen with no homology to MAEBL. c Positive IgG binding was observed with live cells expressing PfMAEBL (in black box). d Serum response 
for all constructs tested for pre-immune and PyMAEBL-immune serum
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of its potential as a vaccine is paramount. Indeed, it has 
recently been shown that M2 MAEBL immunization 
confers 90% mice survival against lethal challenge with P. 
yoelii parasites [4].
Furthermore, the pan-reactivity of the anti-sera raised 
against rPyM2-MAEBL was revealed, which is based on 
the M2 domain of the P. yoelii MAEBL antigen. In addi-
tion, the fact that HEK cells expressing the PvMAEBL 
and the PfMAEBL showed reactivity presents a coun-
ter proof of the pan-reactivity of the anti-sera raised 
against the PyMAEBL M2 region and thus validated the 
ex vivo assays. An IFA pattern different from the article 
published by Leite et al. Was detected [4]. Here, a cyto-
solic staining was observed and previously an apical 
staining was described. This difference could be justi-
fied by the fact that the anti-serum could recognize dif-
ferent Plasmodium proteins. These antibodies were able 
to recognize and inhibit at high levels the invasion of P. 
falciparum and P. vivax (mainly) collected from infected 
patients in Thailand, suggesting that antibodies against 
one Plasmodium species recognize several antigens from 
other species [34, 47, 48] and the presence of homolo-
gous molecules with interspecies conserved epitopes.
Conclusions
Combined immunoinformatics and experimen-
tal approach strategies confirmed the potential of the 
MAEBL antigen as a malaria vaccine candidate. Whilst 
the MAEBL may be unlikely to confer sterile immunity if 
used as the sole component of a vaccine, it may be com-
bined with other antigens towards the synthesis of a fully 
effective chimeric subunit vaccine. Moreover, the P. yoelii 
mouse model can be used to test human malaria parasite 
antigens for their immunogenicity and efficacy as vaccine 
candidates.
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